DPM.F Sumitomo Dainippon Pharma Co. Ltd

Healthcare Pharmaceuticals Frankfurt Exchange
10.73 EUR
Close of Nov 12, 2026
6.65 18.80
Market cap
EUR 4.81B
P/E
18.5x
P/B
2.05x
ROE
0.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is DPM.F undervalued?

Graham number
Price10.73
Graham value8.27
Premium29.7%

DPM.F trades 29.7% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Sumitomo Dainippon Pharma Co. Ltd fundamental analysis

No fundamental analysis for Sumitomo Dainippon Pharma Co. Ltd yet.

Sumitomo Dainippon Pharma Co. Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Sumitomo Dainippon Pharma Co. Ltd

Sumitomo Pharma Co., Ltd. Manufactures, purchases, and sells pharmaceutical products for medical treatment in Japan, North America, and Asia. It offers therapeutic agents for parkinson's disease, type 2 diabetes, uterine fibroids and endometriosis, overactive bladder, and pediatric congenital athymia. The company also provides atypical antipsychotic, generic products, antiepileptic, atypical antipsychotic, and carbapenem antibiotic. In addition, it offers veterinary medicine…

Full company profile